CN101437532B - 噬菌体衍生的抗微生物活性剂 - Google Patents

噬菌体衍生的抗微生物活性剂 Download PDF

Info

Publication number
CN101437532B
CN101437532B CN2007800162540A CN200780016254A CN101437532B CN 101437532 B CN101437532 B CN 101437532B CN 2007800162540 A CN2007800162540 A CN 2007800162540A CN 200780016254 A CN200780016254 A CN 200780016254A CN 101437532 B CN101437532 B CN 101437532B
Authority
CN
China
Prior art keywords
polypeptide
cell wall
phage
protein
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800162540A
Other languages
English (en)
Chinese (zh)
Other versions
CN101437532A (zh
Inventor
S·帕德马纳巴恩
V·D·保罗
R·S·萨拉瓦纳
B·斯里拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berkeley Private Holdings Ltd
Original Assignee
Gangagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101437532(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gangagen Inc filed Critical Gangagen Inc
Priority to CN201310322283.7A priority Critical patent/CN103436507B/zh
Priority to CN201610182492.XA priority patent/CN105884904B/zh
Publication of CN101437532A publication Critical patent/CN101437532A/zh
Application granted granted Critical
Publication of CN101437532B publication Critical patent/CN101437532B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2007800162540A 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂 Expired - Fee Related CN101437532B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201310322283.7A CN103436507B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN201610182492.XA CN105884904B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79788506P 2006-05-05 2006-05-05
US60/797,885 2006-05-05
US90934007P 2007-03-30 2007-03-30
US60/909,340 2007-03-30
PCT/US2007/010972 WO2007130655A2 (en) 2006-05-05 2007-05-04 Phage derived antimicrobial activities

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201310322283.7A Division CN103436507B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN201610182492.XA Division CN105884904B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Publications (2)

Publication Number Publication Date
CN101437532A CN101437532A (zh) 2009-05-20
CN101437532B true CN101437532B (zh) 2013-08-21

Family

ID=38668376

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2007800162540A Expired - Fee Related CN101437532B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN201310322283.7A Expired - Fee Related CN103436507B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN201610182492.XA Expired - Fee Related CN105884904B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201310322283.7A Expired - Fee Related CN103436507B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN201610182492.XA Expired - Fee Related CN105884904B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Country Status (10)

Country Link
US (6) US8202516B2 (enExample)
EP (1) EP2037946B2 (enExample)
JP (4) JP5383481B2 (enExample)
CN (3) CN101437532B (enExample)
CA (1) CA2651125C (enExample)
DK (1) DK2037946T3 (enExample)
ES (1) ES2536852T3 (enExample)
MX (1) MX2008014150A (enExample)
PT (1) PT2037946E (enExample)
WO (1) WO2007130655A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007061929A1 (de) * 2007-12-21 2009-06-25 Profos Ag Proteasestabile Zellwand lysierende Enzyme
EP2157100A1 (en) * 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
US8563504B2 (en) * 2008-10-10 2013-10-22 Lusomedicamenta, S.A. Antibacterial phage peptides and methods of use thereof
EP2338916A1 (en) 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
EP2397548A1 (en) 2010-06-18 2011-12-21 Hyglos Invest GmbH Methods of generating and screening for lytic chimeric polypeptides
ES2825050T3 (es) * 2010-09-17 2021-05-14 Tecnifar Ind Tecnica Farmaceutica S A Fago antibacteriano, péptidos de fago y métodos de uso de los mismos
CA2833176C (en) 2011-04-12 2023-05-16 C.B. Appaiah Chimeric antibacterial polypeptides
PL394619A1 (pl) * 2011-04-19 2012-10-22 Miedzynarodowy Instytut Biologii Molekularnej I Komórkowej Sposób proteolizy, peptydaza, kompozycja do stosowania jako srodek bakteriostatyczny lub bakteriobójczy, zestaw oraz zastosowania aktywnej formy LytM z S. aureus lub jej pochodnej
SG11201406112TA (en) * 2012-03-27 2014-10-30 Genentech Inc Improved harvest operations for recombinant proteins
KR101466620B1 (ko) 2012-06-22 2014-11-28 주식회사 씨티씨바이오 신규한 박테리오파지 및 이의 아에로모나스 히드로필라 증식 억제 용도
KR101381336B1 (ko) 2012-06-25 2014-04-25 주식회사 씨티씨바이오 신규한 박테리오파지 ｐｖｐ-1 및 이의 비브리오 파라헤몰리티쿠스 증식 억제 용도
WO2013191363A1 (ko) * 2012-06-22 2013-12-27 주식회사 씨티씨바이오 신규한 박테리오파지 및 병원성 박테리아 증식 억제 용도
US8980614B2 (en) * 2012-09-06 2015-03-17 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcus haemolyticus prophage φSH2 endolysin is lytic for Staphylococcus aureus
CN106795506B (zh) * 2014-05-14 2020-11-27 达特茅斯学院理事会 去免疫化溶葡萄球菌酶和使用方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109312296B (zh) * 2016-06-14 2023-05-05 帝斯曼知识产权资产管理有限公司 重组酵母细胞
US20190282673A1 (en) * 2016-08-26 2019-09-19 Gangagen, Inc. Staphtame activity on biofilms
CN106635942B (zh) * 2016-12-05 2020-05-29 齐鲁工业大学 一种芽孢表面稳定展示海藻糖合酶的工程菌及其构建方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11236314B2 (en) * 2017-03-30 2022-02-01 Bactoclear Holdings Pte. Ltd Chimeric lysm polypeptides
KR20240162610A (ko) * 2017-04-03 2024-11-15 사시나파스 컴퍼니 리미티드 조작된 그람-음성 엔도리신
CN107502603B (zh) * 2017-09-06 2018-06-05 江苏省农业科学院 一种大肠杆菌裂解酶及其制备方法与应用
CN107828769B (zh) * 2017-09-28 2021-03-02 昆明理工大学 一种耐热裂解酶MMPpgh和编码此酶的多核苷酸
DK3723488T3 (da) 2017-12-14 2025-10-27 Bactoclear Holdings Pte Ltd Terapeutiske bakteriociner
JP7034724B2 (ja) * 2018-01-16 2022-03-14 花王株式会社 ケラチン断片の製造方法
CN113366103A (zh) * 2018-12-21 2021-09-07 诺维信公司 具有肽聚糖降解活性的多肽以及编码其的多核苷酸
KR20220007123A (ko) * 2019-05-08 2022-01-18 파고메드 바이오파르마 게엠베하 신규 가드네렐라 엔도리신 및 이의 용도
WO2021048257A1 (en) * 2019-09-11 2021-03-18 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Bactericidal phage vectors
PL243303B1 (pl) * 2019-10-13 2023-07-31 Miedzynarodowy Inst Biologii Molekularnej I Komorkowej Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania
JP2023510074A (ja) * 2019-10-31 2023-03-13 バクトクリア ホールディングス ピーティーイー エルティーディー． 細菌の選択的溶解のためのキメラタンパク質
CN111187765B (zh) * 2020-02-17 2022-07-15 西北农林科技大学 一种反刍动物瘤胃特异溶菌酶lyz1及其应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR20240036508A (ko) * 2021-05-13 2024-03-20 포지 바이올로직스, 인크. 아데노바이러스성 헬퍼 플라스미드
CN116732013B (zh) * 2022-03-01 2025-07-25 百葵锐(深圳)生物科技有限公司 具有抗菌活性的细胞壁降解酶
AU2024270871A1 (en) * 2023-05-15 2025-11-20 Topaz Biosciences, Inc. Enzymatically active domains from anti-staphylococcal phage proteins
WO2024263589A1 (en) 2023-06-20 2024-12-26 Topaz Biosciences, Inc. Recombinant cell wall hydrolases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008553A1 (en) * 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
AU1705097A (en) * 1996-01-19 1997-08-11 Novo Nordisk Biotech, Inc. Bacterial donor cell useful in conjugation
DE69833377T2 (de) * 1997-07-23 2006-11-16 Ambi Inc. Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
US6365156B1 (en) * 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US6831063B1 (en) * 1999-08-31 2004-12-14 The Wistar Institute Of Anatomy And Biology Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor
US20050214773A1 (en) * 2001-09-21 2005-09-29 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
AU2003261782A1 (en) * 2002-08-28 2004-03-19 Techno Network Shikoku Co., Ltd. Bacteriophages and remedies for bacterial infection
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
IE20060488A1 (en) 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent

Also Published As

Publication number Publication date
CN105884904A (zh) 2016-08-24
WO2007130655A3 (en) 2008-07-17
DK2037946T3 (en) 2015-04-27
US10278398B2 (en) 2019-05-07
JP5383481B2 (ja) 2014-01-08
CN105884904B (zh) 2020-06-16
ES2536852T3 (es) 2015-05-28
JP2018201525A (ja) 2018-12-27
CA2651125A1 (en) 2007-11-15
WO2007130655A2 (en) 2007-11-15
JP2009536033A (ja) 2009-10-08
EP2037946B2 (en) 2023-11-01
CN103436507A (zh) 2013-12-11
JP6685360B2 (ja) 2020-04-22
JP6416803B2 (ja) 2018-10-31
JP5882968B2 (ja) 2016-03-09
US20190297896A1 (en) 2019-10-03
CN103436507B (zh) 2016-04-20
MX2008014150A (es) 2009-02-04
US8202516B2 (en) 2012-06-19
EP2037946B1 (en) 2015-02-25
PT2037946E (pt) 2015-06-04
US20120237491A1 (en) 2012-09-20
US20170318817A1 (en) 2017-11-09
US20220053775A1 (en) 2022-02-24
US20090324576A1 (en) 2009-12-31
CA2651125C (en) 2016-06-28
US8748150B2 (en) 2014-06-10
EP2037946A2 (en) 2009-03-25
JP2014050388A (ja) 2014-03-20
JP2016112020A (ja) 2016-06-23
US9622486B2 (en) 2017-04-18
EP2037946A4 (en) 2010-09-22
CN101437532A (zh) 2009-05-20
US20140369986A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
CN101437532B (zh) 噬菌体衍生的抗微生物活性剂
JP7465418B2 (ja) 治療用バクテリオシン
Grishin et al. Resistance to peptidoglycan-degrading enzymes
Heselpoth et al. Enzybiotics: endolysins and bacteriocins
CA2833176A1 (en) Chimeric antibacterial polypeptides
US20220220464A1 (en) Chimeric lysm poylpeptides
Gouveia Recombinant Antimicrobial Polypeptides as Alternative Antibacterial Agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200923

Address after: Singapore City

Patentee after: Berkeley private Holdings Limited

Address before: California, USA

Patentee before: GangaGen, Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130821

Termination date: 20200504

CF01 Termination of patent right due to non-payment of annual fee